Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 4/2019

Ausgabe 4/2019

Inhaltsverzeichnis ( 25 Artikel )

13.08.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging

Mohammed Albatany, Susan Meakin, Robert Bartha

29.08.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

Hexane partition from Annona crassiflora Mart. promotes cytotoxity and apoptosis on human cervical cancer cell lines

Viviane A. O. Silva, Ana Laura V. Alves, Marcela N. Rosa, Larissa R. V. Silva, Matias E. Melendez, Fernanda P. Cury, Izabela N. F. Gomes, Aline Tansini, Giovanna B. Longato, Olga Martinho, Bruno G. Oliveira, Fernanda E. Pinto, Wanderson Romão, Rosy I. M. A. Ribeiro, Rui M. Reis

31.08.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma

Lei Zhong, Shu Zhou, Rongsheng Tong, Jianyou Shi, Lan Bai, Yuxuan Zhu, Xingmei Duan, Wenzhao Liu, Jinku Bao, Lingyu Su, Qian Peng

08.09.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Muhammed H. Rahaman, Yingyi Yu, Longjin Zhong, Julian Adams, Frankie Lam, Peng Li, Ben Noll, Robert Milne, Jun Peng, Shudong Wang

28.09.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

Hani M. Babiker, Sara A. Byron, William P. D. Hendricks, William F. Elmquist, Gautham Gampa, Jessica Vondrak, Jessica Aldrich, Lori Cuyugan, Jonathan Adkins, Valerie De Luca, Raoul Tibes, Mitesh J. Borad, Katie Marceau, Thomas J. Myers, Linda J. Paradiso, Winnie S. Liang, Ronald L. Korn, Derek Cridebring, Daniel D. Von Hoff, John D. Carpten, David W. Craig, Jeffrey M. Trent, Michael S. Gordon

17.10.2018 | PRECLINICAL STUDIES | Ausgabe 4/2019

Relationship between expression of XRCC1 and tumor proliferation, migration, invasion, and angiogenesis in glioma

Peng-jin Mei, Jin Bai, Fa-an Miao, Zhong-lin Li, Chen Chen, Jun-nian Zheng, Yue-chao Fan

31.10.2018 | PHASE I STUDIES | Ausgabe 4/2019

A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors

Fen Wang, Julian Molina, Daniel Satele, Jun Yin, Vun-Sin Lim, Alex A. Adjei

06.11.2018 | PHASE I STUDIES | Ausgabe 4/2019

Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors

Xiaofei Zhou, Sandeepraj Pusalkar, Swapan K. Chowdhury, Shawn Searle, Yuexian Li, Claudio Dansky Ullmann, Karthik Venkatakrishnan

09.11.2018 | PHASE I STUDIES | Ausgabe 4/2019

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

Elena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, Guillem Argiles, Thibaud Valentin, Cinthya Coronado, Jorge Iglesias, Teresa Macarulla, Sarah Betrian, Salvador Fudio, Katrin Zaragoza, Josep Tabernero, Jean-Pierre Delord

21.11.2018 | PHASE I STUDIES | Ausgabe 4/2019

A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors

Kabir Mody, Aaron S. Mansfield, Lalitha Vemireddy, Peter Nygren, Joachim Gulbo, Mitesh Borad

14.12.2018 | PHASE I STUDIES | Ausgabe 4/2019 Open Access

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

Alexandra Leary, Christophe Le Tourneau, Andrea Varga, Marie-Paule Sablin, Carlos Gomez-Roca, Nicolas Guilbaud, Aurelie Petain, Mariya Pavlyuk, Jean-Pierre Delord

19.12.2018 | PHASE I STUDIES | Ausgabe 4/2019

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma

Theodoros N. Teknos, J. Grecula, A. Agrawal, M. O. Old, E. Ozer, R. Carrau, S. Kang, J. Rocco, D. Blakaj, V. Diavolitsis, B. Kumar, P. Kumar, Q. Pan, M. Palettas, L. Wei, R. Baiocchi, P. Savvides

19.12.2018 | PHASE I STUDIES | Ausgabe 4/2019

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

Lisa Seitz, Lixia Jin, Manmohan Leleti, Devika Ashok, Jenna Jeffrey, Aimee Rieger, Renger G. Tiessen, Gerhard Arold, Joanne B. L. Tan, Jay P. Powers, Matthew J. Walters, Joyson Karakunnel

28.12.2018 | PHASE I STUDIES | Ausgabe 4/2019 Open Access

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

David C. Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert J. Stagg, Anthony Tolcher

01.02.2019 | PHASE I STUDIES | Ausgabe 4/2019

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

Jian-Chun Duan, Zhi-Jie Wang, Lin Lin, Jun-Ling Li, Yan Wang, Hua Bai, Xing-Sheng Hu, Yu-Tao Liu, Xue-Zhi Hao, Hong-Yu Wang, Rui Wan, Xin Wang, Jie Wang

16.04.2019 | PHASE II STUDIES | Ausgabe 4/2019 Open Access

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Jeffrey P. Sharman, Jennifer J. Wheler, Lawrence Einhorn, Afshin Dowlati, Geoffrey I. Shapiro, John Hilton, John M. Burke, Tanya Siddiqi, Nancy Whiting, Shadia I. Jalal

01.06.2019 | PHASE II STUDIES | Ausgabe 4/2019

Phase II study of avelumab in multiple relapsed/refractory germ cell cancer

M. Mego, D. Svetlovska, M. Chovanec, M. Rečkova, K. Rejlekova, J. Obertova, P. Palacka, Z. Sycova-Mila, U. De Giorgi, J. Mardiak

06.06.2019 | PHASE II STUDIES | Ausgabe 4/2019

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Hao Xie, Jun Yin, Manisha H. Shah, Michael E. Menefee, Keith C. Bible, Diane Reidy-Lagunes, Madeleine A. Kane, David I. Quinn, David R. Gandara, Charles Erlichman, Alex A. Adjei

10.12.2018 | SHORT REPORT | Ausgabe 4/2019

Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis

Junho Kang, Changhoon Yoo, Hee-Sang Hwang, Seung-Mo Hong, Kyu-pyo Kim, Sun Young Kim, Yong-Sang Hong, Tae Won Kim, Baek-Yeol Ryoo

17.12.2018 | SHORT REPORT | Ausgabe 4/2019

Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy

Maurizio Viale, Rita Tosto, Valentina Giglio, Giuseppe Pappalardo, Valentina Oliveri, Irena Maric, Maria Addolorata Mariggiò, Graziella Vecchio

10.01.2019 | SHORT REPORT | Ausgabe 4/2019

Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases

Rejitha Suraj, Jasim Al-Rawi, Christopher Bradley

11.02.2019 | SHORT REPORT | Ausgabe 4/2019

An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent

Wang Yan, Chen Xiangyu, Li Ya, Wang Yu, Xu Feng

21.02.2019 | SHORT REPORT | Ausgabe 4/2019

Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report

Kazunori Honda, Shigenori Kadowaki, Kyoko Kato, Nobuhiro Hanai, Yasuhisa Hasegawa, Yasushi Yatabe, Kei Muro

02.04.2019 | Correction | Ausgabe 4/2019

Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL

Jung Jin Hwang, Yong Sook Kim, Taelim Kim, Mi Joung Kim, In Gab Jeong, Je-Hwan Lee, Jene Choi, Sejin Jang, Seonggu Ro, Choung-Soo Kim

24.04.2019 | Correction | Ausgabe 4/2019

Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Glen J. Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise